When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES
暂无分享,去创建一个
[1] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[2] Denis Getsios,et al. Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease , 2012, PharmacoEconomics.
[3] J. Karnon,et al. Cost analysis of a hospital-at-home initiative using discrete event simulation , 2001, Journal of health services research & policy.
[4] J. Caro,et al. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] M. E. Nita,et al. Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil , 2012 .
[6] Murray Krahn,et al. Conceptualizing a Model , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] J. Karnon,et al. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. , 2008, Health technology assessment.
[8] Jonathan D. Campbell,et al. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes , 2011, Cost effectiveness and resource allocation : C/E.
[9] G. Nocea,et al. Cost‐effectiveness of sitagliptin‐based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy , 2008, Diabetes, obesity & metabolism.
[10] A. Brennan,et al. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. , 2010, International journal of cardiology.
[11] J. Möller,et al. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib , 2011, Journal of medical economics.
[12] E. Buskens,et al. The cost-effectiveness of atypicals in the UK. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] M. Nita,et al. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. , 2012, Revista da Associacao Medica Brasileira.
[14] T. Psaltopoulou,et al. Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece , 2013, Cancer management and research.
[15] P. McEwan,et al. Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany , 2012, Clinical Drug Investigation.
[16] R. Holman,et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.
[17] A. Tsai. Cost-Effectiveness of Herpes Zoster Vaccine , 2006 .
[18] Alexandra Ward,et al. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK , 2006, Current medical research and opinion.
[19] Irina Proskorovsky,et al. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] Maureen A Smith,et al. Retrospective cost-effectiveness analysis of screening mammography. , 2006, Journal of the National Cancer Institute.
[21] Mirjam Kretzschmar,et al. Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model , 2010, PloS one.
[22] S. Brailsford,et al. The evaluation of screening policies for diabetic retinopathy using simulation , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[23] D. Nathwani,et al. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation , 2010, Current medical research and opinion.
[24] Murray Krahn,et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] Alexandra Ward,et al. Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[26] J. Staffurth,et al. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).
[27] Kelly Cho,et al. Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps , 2012, International journal of Alzheimer's disease.
[28] D. Owens,et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] P. Anaya,et al. Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation. , 2012, Value in health regional issues.
[30] J. Norrefalk,et al. A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting , 2012, Journal of medical economics.
[31] J. Gagliardino,et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina , 2013, Health Economics Review.
[32] Jaime J Caro,et al. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? , 2007, PharmacoEconomics.
[33] M. Ekman,et al. Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode , 2012, PharmacoEconomics.
[34] J. Karnon,et al. Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer , 2012, PharmacoEconomics.
[35] Jonathan Karnon,et al. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective , 2008, The European Journal of Health Economics.
[36] J. Caro,et al. A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data , 2011, PharmacoEconomics.
[37] C. Marra,et al. Cost Effectiveness of Herpes Zoster Vaccine in Canada , 2012, PharmacoEconomics.
[38] A. Burroughs,et al. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis , 2007, Current medical research and opinion.
[39] Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. , 2003, Journal of medical screening.
[40] Walter J. Jones,et al. Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV , 2012, PharmacoEconomics.
[41] Alexandra Ward,et al. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone , 2007, Current medical research and opinion.
[42] Jonathan Karnon,et al. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.
[43] Rodolfo Saracci,et al. Everything should be made as simple as possible but not simpler. , 2006, International journal of epidemiology.
[44] D. Yin,et al. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes‐related complications , 2008, Diabetes, obesity & metabolism.
[45] J Karnon,et al. Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.
[46] Jonathan Karnon,et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[47] The cost-effectiveness of paliperidone extended release in Spain , 2012, Journal of medical economics.
[48] J. Caro,et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. , 2005, Journal of cardiac failure.
[49] Peter Lindgren,et al. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden , 2009, International Journal of Technology Assessment in Health Care.
[50] M. Löthgren,et al. Cost effectiveness of long-acting risperidone in Sweden , 2010, Applied health economics and health policy.
[51] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[52] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[53] P. Schädlich,et al. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany , 2012, Journal of medical economics.
[54] A. Boonen,et al. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis , 2011, Annals of the rheumatic diseases.
[55] M. Neyt,et al. Cost Effectiveness of Drug-Eluting Stents In Belgian Practice , 2012, PharmacoEconomics.
[56] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[57] J. Caro,et al. Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder , 2007, Expert review of pharmacoeconomics & outcomes research.
[58] Jonathan Karnon,et al. Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases , 2013, Applied Health Economics and Health Policy.
[59] Johan L Severens,et al. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[60] G. Laux,et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany , 2012, PharmacoEconomics.
[61] J. Barendregt,et al. Cost-Effectiveness of Total Hip and Knee Replacements for the Australian Population with Osteoarthritis: Discrete-Event Simulation Model , 2011, PloS one.
[62] R. Wasiak,et al. Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany , 2010, Journal of medical economics.